Orbitale Fettgewebsatrophie bei lokaler Bimatoprost-Therapie - Kann Bimatoprost einen Enophthalmus verursachen?

Tappeiner, C.; Perren, B.; Iliev, Milko E; Frueh, B. E.; Goldblum, David

doi:10.1055/s-2008-1027362

Cited by 46 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some patients the disparity of periorbital appearance between the treated eye and the fellow eye returned to normal after discontinuation of the ophthalmic prostaglandin analogs or prostamide for a relatively long interval 66,68. The exact mechanism is uncertain, but fatty degeneration and reduced collagen fibers in the levator complex caused by the prostaglandin or prostamide analogs have been proposed as a possible mechanism 66,68…”

Section: Safetymentioning

confidence: 99%

Bimatoprost in the treatment of eyelash hypotrichosis

Law¹

2010

OPTH

View full text Add to dashboard Cite

Eyelashes hypotrichosis is a condition indicated by an inadequate amount of eyelashes. Hypertrichosis of eyelashes, characterized by excessive eyelash growth, is a regular phenomenon associated with ophthalmic prostaglandin and prostamide analogs. Recently, the US Food and Drug Administration approved Latisse® (bimatoprost 0.03% solution), identical to the ophthalmic solution for glaucoma treatment, for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes. When prostaglandin and prostamide analogs interact with the prostanoid receptors in the hair follicle, this most likely stimulates the resting follicles (telogen phase) to growing follicles (anagen phase). Prostaglandin and prostamide analogs may also prolong the anagen phase of eyelashes, leading to an increase of eyelash length. Although bimatoprost is effective in promoting increased growth of healthy eyelashes and adnexal hairs, its effectiveness in patients with eyelash alopecia areata is debatable and its protective effect is not yet studied in patients with eyelash loss secondary to radiation or chemotherapy. Bimatoprost is generally safe when applied to the base of the eyelashes at the lid margin with minimum side effects. However, other ocular or systemic side effects associated with ophthalmic prostaglandin and prostamide analogs may occur when instilled on the surface of the eye, and patients must be informed and monitored.

show abstract

Section: Safetymentioning

confidence: 99%

Bimatoprost in the treatment of eyelash hypotrichosis

Law¹

2010

OPTH

View full text Add to dashboard Cite

show abstract

“…Since Peplinski and Albiani Smith [4] first reported the upper eyelid sulcus deepening and dermatochalasis involution in three Caucasian patients treated with bimatoprost unilaterally, other similar clinical observations have been reported [5,6,7,8,9,10]. Previous studies suggest that the common pathophysiologic mechanism of periocular changes by PG analogues is atrophy of preaponeurotic and deep orbital fat [6,7].…”

Section: Discussionmentioning

confidence: 69%

“…Previous studies suggest that the common pathophysiologic mechanism of periocular changes by PG analogues is atrophy of preaponeurotic and deep orbital fat [6,7]. A recent histological study also suggests orbital fat atrophy as a mechanism of upper eyelid sulcus deepening in topical PG analog users, including those using bimatoprost [10].…”

Section: Discussionmentioning

confidence: 99%

“…However, the use of these drugs may lead to adverse effects such as darkening of the periocular skin and iris, increased eyelash growth, cystoid macular edema, and conjunctival hyperemia [3]. Deepening of the upper lid sulcus and decreased dermatochalasis have been reported in topical PG users [4,5,6,7,8,9]. Recent clinical investigation suggests that fat atrophy is a possible mechanism for the development of a deep superior sulcus [10].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Topical Prostaglandin Analogue Drugs Inhibit Adipocyte Differentiation

Kim

2014

Korean J Ophthalmol

View full text Add to dashboard Cite

PurposeTo investigate the effects of topical prostaglandin analogue drugs on the differentiation of adipocytes.MethodsDifferentiation of 3T3-L1 preadipocytes was induced with isobutylmethylxanthine, dexamethasone, and insulin. 3T3-L1 cells were exposed to 0.008, 0.08, 0.2 µM of latanoprost and travoprost. Reverse transcription polymerase chain reaction for mRNA expression of lipoprotein lipase and peroxisome proliferator-activated receptor γ 2 (PPARγ2), and glycerol-3-phosphate dehydrogenase (G3PDH) assays were performed to examine the effects on early and late differentiation, respectively. Also, glycerol assays were done to evaluate the effect of prostaglandin analogues on lipolysis after differentiation.ResultsBoth prostaglandin analogues inhibited differentiation of preadipocytes. Topical prostaglandin analogues significantly decreased G3PDH activity, a marker of late differentiation. However, topical prostaglandin analogues did not change mRNA expressions of lipoprotein lipase and PPARγ2, markers of early differentiation. The activities of the early markers of differentiation were not changed significantly before and after growth arrest. Compared to latanoprost, travoprost decreased G3PDH activity more significantly (p < 0.05). Both prostaglandin analogues did not affect the lipolysis of differentiated adipocytes (p > 0.05).ConclusionsProstaglandin analogues display an inhibitory effect on the differentiation of adipocytes when the cells start to differentiate especially in the late stage of differentiation. Thus, commercial topical prostaglandin analogues may decrease the fat contents of eyelids.

show abstract

“…The mechanism of PG-induced DUES has been proposed to be as follows. Via activation of the prostanoid FP receptor, PG analogs decrease fat production in the orbital fat tissue; consequently, the orbital volume is reduced, deepening the eyelid sulcus [11, 16–21]. However, the incidence of DUES has been shown to differ depending on the type of PG analog.…”

Section: Discussionmentioning

confidence: 99%

Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy

et al. 2017

View full text Add to dashboard Cite

For primary open angle glaucoma (POAG), laser treatment or surgery is used when the target intraocular pressure (IOP) cannot be achieved by pharmacological agents, such as prostaglandin (PG) analogs; these drugs also have varied effects. We retrospectively reviewed the medical records of 74 POAG patients (74 eyes) whose IOP was inadequately controlled by PG analogs (bimatoprost [13 eyes], latanoprost [34 eyes], tafluprost [11 eyes], and travoprost [16 eyes]) and underwent primary trabeculectomy. The proportion of patients with no recurrent IOP elevation within 24 months post-trabeculectomy was significantly (P < 0.001) lower in the bimatoprost group (31.3%) than in the latanoprost (83.2%), tafluprost (45.5%), or travoprost groups (65.6%). Deepening of the upper eyelid sulcus (DUES) was observed before trabeculectomy in 18 of 74 eyes (24.3%) treated with bimatoprost (9 eyes; 50.0%), latanoprost (3 eyes; 16.7%), tafluprost (1 eye; 5.5%) and travoprost (5 eyes; 27.8%). The proportion of patients with no recurrent IOP elevation up to 24 months post-trabeculectomy was significantly (P < 0.0001) lower in the DUES(+) group (34.7%) than in the DUES(-) group (74.3%). Multivariate stepwise logistic regression analysis, with no recurrent IOP elevation used as dependent variable, and bimatoprost, latanoprost, travoprost, tafluprost, β-blocker, carbonic anhydrase inhibitor, brimonidine, gender, age, preoperative IOP, mean deviation, duration of PG analog use before surgery, and the number of ophthalmic solutions used as independent variables, identified only bimatoprost as a significant independent factor (P = 0.0368). Thus, the outcome of trabeculectomy varied depending on the PG analog used preoperatively, and bimatoprost use was associated with a high risk of recurrent IOP elevation up to 2 years post-trabeculectomy. This may indicate that the incidence of DUES differed with the PG analog used. Patients with glaucoma who are treated with bimatoprost should be monitored for DUES, and when these patients undergo trabeculectomy, the postoperative course of IOP should be followed carefully.

show abstract

Orbitale Fettgewebsatrophie bei lokaler Bimatoprost-Therapie - Kann Bimatoprost einen Enophthalmus verursachen?

Cited by 46 publications

References 7 publications

Bimatoprost in the treatment of eyelash hypotrichosis

Bimatoprost in the treatment of eyelash hypotrichosis

Topical Prostaglandin Analogue Drugs Inhibit Adipocyte Differentiation

Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy

Contact Info

Product

Resources

About